Q-omics provides the consensus-scored KRT18P6 profile across patient tissues and cancer cell-line models. KRT18P6 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KRT18P6 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, KRT18P6 RNA expression shows 8,986 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, STAD, and TGCT as cancer lineages where KRT18P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P6 survival associations across molecular data types. KRT18P6 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P6 RNA expression–survival associations across cancer types. High KRT18P6 expression shows unfavorable associations in ACC, BLCA, KIRP, KIRC, DLBC and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KRT18P6 RNA expression.
This table summarizes KRT18P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P6 shows lower tumor expression in BLCA and higher tumor expression in STAD, BRCA, LIHC, HNSC and PRAD. The STAD box plot shows higher KRT18P6 RNA expression in tumor versus normal tissue (log2 FC = +0.055, t-test p < 0.001).
This table shows molecular features associated with KRT18P6 in patient tissues and cancer cell lines. In patient samples, KRT18P6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
